The U.S. Supreme Court recently engaged in oral arguments on a pivotal case involving the Food and Drug Administration’s (FDA) refusal to approve flavored e-cigarettes, a decision the agency justified on grounds of public health. This legal dispute foregrounds two companies, Triton Distribution and Vapetesia, whose applications to market flavored e-cigarette liquids were denied by the FDA under the guidelines of the Family Smoking Prevention and Tobacco Control Act. This act mandates that new tobacco products must demonstrate suitability for public health protection before they gain market entry.
Previously, a ruling by the Fifth Circuit court criticized the FDA for allegedly misguiding these companies regarding scientific evidence standards. The court deemed that the FDA had violated administrative law, accusing it of sending businesses on a “wild goose chase” and partaking in “regulatory switcheroos”. Judge Andrew Oldham, who authored the court’s opinion, indicated that the agency rejected applications without a sincere examination of the companies’ efforts to combat youth smoking. The FDA has since appealed this decision to the Supreme Court (Read Court Decision).
During the Supreme Court hearing, discussions largely centered on whether the FDA provided adequate notice to applicants about the crucial role of scientific evidence. Counsel for the vape companies, Eric Heyer, contended that the FDA had shifted its criteria emphasis unfairly, placing substantial weight on scientific over marketing evidence without proper forewarning. Conversely, the FDA maintained that overlooking the applicants’ marketing plans represented a “harmless error”. This legal nuance implies that procedural errors by an agency should not lead to a decision’s reversal unless such errors significantly impinge on case outcomes.
While several justices, including Justice Kavanaugh, acknowledged the discretionary power of the FDA stipulated by existing statutes, their inquiries suggested a degree of support for the FDA’s argument of “harmless error”. Despite the skepticism facing the vape companies’ position, the Supreme Court’s decision in this matter remains pending, leaving its impact on public health policy and administrative law yet to be fully realized.
Further reading and insights regarding the hearing and its potential implications can be found here.